Jon also eJon also emphasized that these companies including Reata and Sonelo were targeting single indication only whereas NNZ2561 has the potential to treat multiple indications
- Forums
- ASX - By Stock
- NEU
- Ann: Phase 2 trial shows significant improvements in Pitt Hopkins
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-73
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$15.66 |
Change
-1.055(6.31%) |
Mkt cap ! $2.000B |
Open | High | Low | Value | Volume |
$16.61 | $16.65 | $15.54 | $5.366M | 338.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 278 | $15.65 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.66 | 62 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 522 | 15.670 |
7 | 916 | 15.660 |
20 | 1170 | 15.650 |
9 | 1477 | 15.640 |
7 | 1379 | 15.630 |
Price($) | Vol. | No. |
---|---|---|
15.690 | 322 | 5 |
15.700 | 422 | 8 |
15.710 | 390 | 6 |
15.720 | 369 | 3 |
15.730 | 1317 | 6 |
Last trade - 15.02pm 18/11/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online